The company’s data package includes three Proffered Paper presentations and three Rapid Oral sessions, covering more than ten distinct oncology areas. Key highlights include phase 3 results for its HER2-targeted trastuzumab rezetecan in advanced breast cancer and interim data for the HER3-targeted ruzaltatug rezetecan in EGFR-mutated non-small-cell lung cancer. Both candidates represent the core of the firm's expanding ADC development platform.
In section Releases
Hengrui Pharma to Present Record 64 Research Findings at ESMO 2026
Hengrui Pharma will showcase 64 research findings at the European Society for Medical Oncology Congress in Madrid this October, marking the company's eleventh consecutive appearance at the event. The presentations will highlight advancements in antibody-drug conjugates and novel therapies for challenging malignancies like pancreatic cancer.
Beyond these targets, Hengrui is addressing difficult-to-treat cancers through its KRAS G12D inhibitor, HRS-4642. Preliminary phase 2 results for a combination regimen involving this inhibitor will be featured as a Rapid Oral presentation, signaling a strategic push into targeted therapies for specific genetic mutations. The company will also host an exhibition booth for the second year, facilitating international scientific exchange as it transitions its R&D focus toward global clinical applications.
Comments (0)
No comments yet. Be the first!